Savara Earnings Reports

In Q4 2024, Savara posted a net loss of $29.04 million or $(0.13) per share, primarily due to increased investment in research and development and commercial preparation for MOLBREEVI. The company ended the quarter with strong liquidity, holding $196.33 million in cash and short-term investments.

Savara reported a net loss attributable to common stockholders of $9.4 million, or $(0.16) per share, for the three months ended June 30, 2020. The company had cash, cash equivalents, and short-term investments of approximately $100 million as of June 30, 2020.

Savara reported a net loss attributable to common stockholders of $15.4 million, or $(0.27) per share, for the three months ended March 31, 2020. As of March 31, 2020, Savara had cash, cash equivalents, and short-term investments of approximately $105 million.

Savara reported positive results from the IMPALA open-label follow-up, is planning an additional Phase 3 study of Molgradex for aPAP, and announced top-line microbiology data from OPTIMA. The company's net loss for the fourth quarter of 2019 was $31.7 million, or $(0.72) per share.